scispace - formally typeset
C

Chenguang Liang

Researcher at University of California, San Diego

Publications -  6
Citations -  72

Chenguang Liang is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Glycosylation & Medicine. The author has an hindex of 3, co-authored 5 publications receiving 41 citations. Previous affiliations of Chenguang Liang include University of California, Berkeley.

Papers
More filters
Posted ContentDOI

Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity

TL;DR: It is shown that commensal host bacterial communities can modify HS and thereby modulate SARS-CoV-2 spike protein binding and that these communities change with host age and sex.
Journal ArticleDOI

A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering

TL;DR: This modeling approach enables rational glycoengineering and the elucidation of relationships between glycosyltransferases, thereby facilitating biopharmaceutical research and aiding the broader study of Glycosylation to elucidate the genetic basis of complex changes in glycosYLation.
Journal ArticleDOI

A consensus-based and readable extension of Linear Code for Reaction Rules (LiCoRR).

TL;DR: Linear Code for Reaction Rules (LiCoRR), version 1.0, is presented, an unambiguous representation for describing glycosylation reactions in both literature and code to minimize inconsistent symbology thereby making glycan database queries easier.
Journal ArticleDOI

Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.

TL;DR: The role of aberrant glycosylation in this process, and how it influences tumor immunity and immunotherapy is beginning to emerge as discussed by the authors, and the emerging technologies in systems glycobiology are enabling deeper insights into cancer immuno-oncology, helping identify novel drug targets and key biomarkers of cancer, and facilitating the rational design of glyco-immunotherapies.